JP2022512541A5 - - Google Patents
Info
- Publication number
- JP2022512541A5 JP2022512541A5 JP2021511588A JP2021511588A JP2022512541A5 JP 2022512541 A5 JP2022512541 A5 JP 2022512541A5 JP 2021511588 A JP2021511588 A JP 2021511588A JP 2021511588 A JP2021511588 A JP 2021511588A JP 2022512541 A5 JP2022512541 A5 JP 2022512541A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cancer
- binding
- pharmaceutical composition
- extracellular domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724600P | 2018-08-29 | 2018-08-29 | |
| US62/724,600 | 2018-08-29 | ||
| US201862734951P | 2018-09-21 | 2018-09-21 | |
| US62/734,951 | 2018-09-21 | ||
| US201962793235P | 2019-01-16 | 2019-01-16 | |
| US62/793,235 | 2019-01-16 | ||
| US201962832830P | 2019-04-11 | 2019-04-11 | |
| US62/832,830 | 2019-04-11 | ||
| US201962890217P | 2019-08-22 | 2019-08-22 | |
| US62/890,217 | 2019-08-22 | ||
| PCT/US2019/048923 WO2020047328A1 (en) | 2018-08-29 | 2019-08-29 | Combination therapies comprising pd-1-based chimeric proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512541A JP2022512541A (ja) | 2022-02-07 |
| JP2022512541A5 true JP2022512541A5 (cg-RX-API-DMAC7.html) | 2022-09-06 |
Family
ID=69644684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511588A Pending JP2022512541A (ja) | 2018-08-29 | 2019-08-29 | Pd-1系キメラタンパク質を含む併用療法 |
| JP2021511586A Ceased JP2022511286A (ja) | 2018-08-29 | 2019-08-29 | Sirpアルファ系キメラタンパク質を含む併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511586A Ceased JP2022511286A (ja) | 2018-08-29 | 2019-08-29 | Sirpアルファ系キメラタンパク質を含む併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20210379153A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3844176A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022512541A (cg-RX-API-DMAC7.html) |
| CN (2) | CN112771067A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019327493A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3109354A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL281095A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2021002292A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2020047328A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111278865B (zh) * | 2017-10-26 | 2023-04-25 | 盛禾(中国)生物制药有限公司 | 新的重组融合蛋白及其制备和用途 |
| MX2021002292A (es) * | 2018-08-29 | 2021-05-27 | Shattuck Labs Inc | Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa. |
| US20210301019A1 (en) * | 2020-03-26 | 2021-09-30 | Aetio Biotherapy, Inc. | Bi-specific fusion proteins for depletion of regulatory t cells |
| WO2022053864A1 (en) * | 2020-09-08 | 2022-03-17 | Kwon Byoung S | Pd-1 polypeptide variants |
| IL301454A (en) * | 2020-09-17 | 2023-05-01 | Shattuck Labs Inc | Clinical dosing of SIRP1A chimeric protein |
| US20230414778A1 (en) * | 2020-11-11 | 2023-12-28 | Daiichi Sankyo Company, Limited | COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY |
| AU2021390545A1 (en) * | 2020-12-03 | 2023-07-06 | Shattuck Labs, Inc. | Methods of treating cancer using tigit-and light-based chimeric proteins |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
| CN117321079A (zh) * | 2021-01-11 | 2023-12-29 | 优特力克斯有限公司 | 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途 |
| CN117355336A (zh) * | 2021-03-05 | 2024-01-05 | 沙塔克实验室有限公司 | 基于SIRP α的嵌合蛋白的联合疗法 |
| JP2024508540A (ja) * | 2021-03-05 | 2024-02-27 | シャタック ラボ,インコーポレイテッド | SIRPαベースのキメラタンパク質を用いた併用療法 |
| MX2024005649A (es) * | 2021-11-12 | 2024-07-10 | Shattuck Labs Inc | Proteinas quimericas basadas en sirp1a y cd40l. |
| CN120923632A (zh) * | 2022-05-06 | 2025-11-11 | 正大天晴药业集团股份有限公司 | 靶向cd40和cd47的重组融合蛋白 |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| JPH07509694A (ja) | 1992-05-14 | 1995-10-26 | ベイラー・カレッジ・オブ・メディシン | 突然変異したステロイドホルモン受容体,その使用方法および遺伝子治療のための分子スイッチ |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6004941A (en) | 1993-06-14 | 1999-12-21 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| EP0770397B1 (en) | 1995-10-18 | 2004-04-21 | Akzo Nobel N.V. | Newcastle disease virus combination vaccine |
| US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
| US5989910A (en) | 1998-08-03 | 1999-11-23 | University Of Lausanne | Potent genetic switch allowing regulated gene expression in eukaryotic cells |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| AU2009298131B2 (en) * | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| ME03550B (me) * | 2012-12-17 | 2020-07-20 | Trillium Therapeutics Inc | Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama |
| PE20151921A1 (es) * | 2013-03-14 | 2015-12-26 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle y usos de los mismos |
| EA201690912A1 (ru) * | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| US10046047B2 (en) * | 2015-02-06 | 2018-08-14 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
| SG10201913573UA (en) | 2015-10-01 | 2020-03-30 | Heat Biologics Inc | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| WO2018118664A1 (en) * | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| DK3565579T3 (da) * | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| IL268198B2 (en) | 2017-02-27 | 2024-10-01 | Shattuck Labs Inc | Tigit- and light-based chimeric proteins |
| CN107857819A (zh) * | 2017-07-03 | 2018-03-30 | 江苏西迪尔生物技术有限公司 | 多功能融合蛋白及其应用 |
| MX2021002292A (es) * | 2018-08-29 | 2021-05-27 | Shattuck Labs Inc | Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa. |
-
2019
- 2019-08-29 MX MX2021002292A patent/MX2021002292A/es unknown
- 2019-08-29 CN CN201980063224.8A patent/CN112771067A/zh active Pending
- 2019-08-29 MX MX2021002294A patent/MX2021002294A/es unknown
- 2019-08-29 EP EP19855662.3A patent/EP3844176A4/en not_active Withdrawn
- 2019-08-29 JP JP2021511588A patent/JP2022512541A/ja active Pending
- 2019-08-29 AU AU2019327493A patent/AU2019327493A1/en not_active Abandoned
- 2019-08-29 CA CA3109354A patent/CA3109354A1/en active Pending
- 2019-08-29 CA CA3109346A patent/CA3109346A1/en active Pending
- 2019-08-29 WO PCT/US2019/048923 patent/WO2020047328A1/en not_active Ceased
- 2019-08-29 AU AU2019327494A patent/AU2019327494A1/en not_active Abandoned
- 2019-08-29 WO PCT/US2019/048913 patent/WO2020047319A1/en not_active Ceased
- 2019-08-29 CN CN201980067213.7A patent/CN112839952A/zh active Pending
- 2019-08-29 EP EP19853526.2A patent/EP3844175A4/en not_active Withdrawn
- 2019-08-29 JP JP2021511586A patent/JP2022511286A/ja not_active Ceased
- 2019-08-29 US US17/266,015 patent/US20210379153A1/en not_active Abandoned
- 2019-08-29 US US17/266,356 patent/US20210309744A1/en not_active Abandoned
- 2019-09-16 US US16/571,860 patent/US20200071380A1/en not_active Abandoned
-
2021
- 2021-02-24 IL IL281095A patent/IL281095A/en unknown
- 2021-02-25 IL IL281132A patent/IL281132A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022511286A5 (cg-RX-API-DMAC7.html) | ||
| CN110869388B (zh) | 用于肿瘤特异性细胞消耗的Fc优化的抗CD25 | |
| JP2024532485A (ja) | Cd137および腫瘍関連抗原に結合する二重特異性結合タンパク質 | |
| AU2017247880B2 (en) | Anti CD25 FC gamma receptor bispecific antibodies for tumor specific cell depletion | |
| JP2023509323A5 (cg-RX-API-DMAC7.html) | ||
| JP2024125370A (ja) | クローディン18.2結合部分およびその利用 | |
| JP7102670B2 (ja) | 抗pd‐l1抗体とil‐7との融合 | |
| JP6840127B2 (ja) | がんの治療における抗pd−1抗体および抗m−csf抗体の併用 | |
| JP7464525B2 (ja) | 標的療法のためのチェックポイント遮断を組み合わせる二官能性タンパク質 | |
| JP2020530298A5 (cg-RX-API-DMAC7.html) | ||
| US20160235842A1 (en) | Medical uses of cd38 agonists | |
| JP2017506217A (ja) | 標的TGFβ阻害 | |
| CA3146777A1 (en) | Anti-pd-1 antibody and pharmaceutical use thereof | |
| US20240018248A1 (en) | An ltbr agonist in combination therapy against cancer | |
| JP7362614B2 (ja) | 癌治療のために免疫チェックポイントを調節する単一特異性および二重特異性タンパク質 | |
| CN115192718A (zh) | 抗cd47的单克隆抗体及其用途 | |
| AU2017239038B2 (en) | Administration of an anti-LGR5 monoclonal antibody | |
| JP2022512539A5 (cg-RX-API-DMAC7.html) | ||
| CN115197325A (zh) | 抗体在抗肿瘤治疗中的用途 | |
| JP2025118769A5 (cg-RX-API-DMAC7.html) | ||
| CN119403831A (zh) | 包含nrp1结合结构域的双特异性抗体及其使用方法 | |
| WO2019053613A2 (en) | POLY THERAPY FOR THE TREATMENT OF CANCER | |
| CN114616251A (zh) | 靶向PD-1和TGFβ的重组蛋白 | |
| JP7832689B2 (ja) | Pd-1ポリペプチド変異体 | |
| JP2022503621A5 (cg-RX-API-DMAC7.html) |